Sfoglia per AUTORE
BEDOGNI A
Collezione ASL Alessandria
Items : 8
MRONJ in breast cancer patients under bone modifying agents for cancer treatment-induced bone loss (CTIBL): a multi-hospital-based case series. in BMC oral health / BMC Oral Health. 2023 Feb 4;23(1):71. doi: 10.1186/s12903-023-02732-6.
2023
AOU Alessandria
ASL Alessandria
Oteri G; Campisi G; Toro C; Isola G; Leonardi RM; Giudice A; Graziani F; Marcianò A; Nisi M; Bettini G; Fusco V; Attanasio M; Bedogni A; Coppini M; Mauceri R;
One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ). in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer / Support Care Cancer. 2022 Sep;30(9):7047-7051. doi: 10.1007/s00520-022-06982-y. Epub 2022 Mar 21.
2022
ASL Alessandria
AOU Alessandria
Fusco V; Bedogni A; Campisi G;
The preventive care of medication-related osteonecrosis of the jaw (MRONJ): a position paper by Italian experts for dental hygienists. in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer / Support Care Cancer. 2022 Aug;30(8):6429-6440. doi: 10.1007/s00520-022-06940-8. Epub 2022 Mar 16.
2022
ASL Alessandria
AOU Alessandria
Campisi G; Panzarella V; Mauceri R; Coniglio R; Abbinante A; Carcieri P; Fusco V; Bedogni A; Bertoldo F; Di Fede O; Tomassi D;
A pragmatic window of opportunity to minimise the risk of MRONJ development in individuals with osteoporosis on Denosumab therapy: a hypothesis. in Head & face medicine / Head Face Med. 2021 Jul 9;17(1):25. doi: 10.1186/s13005-021-00280-4.
2021
ASL Alessandria
AOU Alessandria
Bedogni A; Mauceri R; Fusco V; Bertoldo F; Campisi G;
Adjuvant denosumab in early breast-cancer. in The Lancet. Oncology / Lancet Oncol. 2020 Mar;21(3):e124. doi: 10.1016/S1470-2045(20)30066-8.
2020
ASL Alessandria
AOU Alessandria
Campisi G; Bedogni A; Fusco V;
Comment on Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline Summary. in JCO oncology practice / JCO Oncol Pract. 2020 Mar;16(3):142-145. doi: 10.1200/JOP.19.00645. Epub 2020 Jan 24.
2020
ASL Alessandria
AOU Alessandria
Santini D; Fusco V; Campisi G; Bertoldo F; Lanzetta G; Ibrahim T; Bertetto O; Numico G; Addeo A; Berruti A; Bettini G; Saia G; Bedogni A;
Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. A Commentary of the Pivotal Trial by Raje et al. Published on Lancet Oncology. in Dentistry journal / Dent J (Basel). 2018 Sep 1;6(3):42. doi: 10.3390/dj6030042.
2018
ASL Alessandria
AOU Alessandria
Numico G; Bedogni A; Baraldi A; Monaco F; Fusco V; de Boissieu P; Campisi G;
Epidemiology, clinical manifestations, risk reduction and treatment strategies of jaw osteonecrosis in cancer patients exposed to antiresorptive agents in Future Oncology
2014
ASL Alessandria
AOU Alessandria
Bedogni A; Di Fede O; Pizzo G; Fedele S; Fusco V; Campisi G;